Actemra
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
PO Box 2106, Morristown, New Jersey, 079...Website
www.actemra.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Actemra
ACTEMRA is a prescription medicine used to treat adults with rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and systemic sclerosis-associated interstitial lung disease. It is also approved for treating hospitalized adults with COVID-19. ACTEMRA can cause serious side effects such as infections, liver problems, changes in blood test results, cancer risks, allergic reactions, and nervous system issues. Patients should provide detailed medical history before taking ACTEMRA to ensure safety and efficacy.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Actemra your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Actemra launches new products
Funding: Get notified immidiatlly once Actemra has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Actemra, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Actemra
Click to see if Actemra had a recent Job posting/layoffs
Check if Actemra has recently received funding, and reach out quickly before it becomes old news!
Check out if Actemra is spiking on competitors!
Earning: See what the market has to say on Actemra recently announced quarterly report
Recommended Actions
Find VP level buyers at Actemra
Find 2 more new buyers
Compare Similar Companies to Actemra
Compare insights from companies similar to Actemra, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Actemra
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Actemra is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Actemra is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Actemra.
Actemra Tech Stack
A closer look at the technologies used by Actemra
See more technologies
Actemra News & Media
Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra® (tocilizumab) for the treatment of COVID-19 in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or eGenentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the global Phase III randomized, double-blind, multicenter REMDACTA study of Actemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were ideCOVID-19 Wins and Losses: Genentech’s Actemra Flunks Trial; Vir & GSK’s Antibody Dazzles
Genentech reported its rheumatoid arthritis drug Actemra failed to hit its primary endpoint in a COVID-19 trial, while Vir and GlaxoSmithKline’s antibody against COVID-19 demonstrated 85% efficacy.Genentech’s Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating Condition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Actemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra is the first biologic therapy approved by the FDA for t
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Actemra
Sign Up For FreeTo access detailed company insights
ACTEMRA is a prescription medicine used to treat adults with rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and systemic sclerosis-associated interstitial lung disease. It is also approved for treating hospitalized adults with COVID-19. ACTEMRA can cause serious side... Read More
